Novel Nucleic Acid Sequencing Technology Development (R01, R21, R43/R44)

Funding Agency:
National Institutes of Health

This Funding Opportunity Announcement (FOA) solicits R01 grant applications to develop novel technologies that will enable substantive (no less than one order of magnitude) improvement in synthetic nucleic acids. The goal is to improve the quality, capabilities and efficiency of nucleic acid synthesis and synthetic constructs at reasonable and decreased costs. Large progress in this area has the potential to catalyze scientific advances relevant to the mission of NIH, NHGRI and the field of genomics.

Although this funding opportunity uses the R01 grant mechanism, it runs in parallel with two program announcements of identical scientific scope: RFA-HG-20-015, for exploratory/developmental (R21) grants, and RFA-HG-20-016, for R43/R44 SBIR grants.

Deadlines:

  • Letter of Intent Due Date(s): 30 days prior to the application due date
  • Application Due Date(s): New Dates June 24, 2020; March 9, 2021; February 4, 2022

​RFA-HG-20-014 Expiration Date New Date February 5, 2022 per issuance of NOT-HG-21-005. (Original Expiration Date: June 25, 2022)

Agency Website

Amount

$2,100,000

Amount Description

An applicant may request direct costs of up to $700,000 per year.  Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary.

The scope of the proposed project should determine the project period. The maximum project period is 3 years.

    Funding Type

    Grant

    Eligibility

    Faculty

    Category

    Curriculum Development
    Engineering and Physical Sciences
    Medical
    Medical - Basic Science
    Medical - Clinical Science
    Medical - Translational

    External Deadline

    February 4, 2022